Literature DB >> 31654942

Trends in transcatheter and operative closure of patent ductus arteriosus in neonatal intensive care units: Analysis of data from the Pediatric Health Information Systems Database.

Michael L O'Byrne1, Marisa E Millenson2, Connor B Grady3, Jing Huang4, Nicolas A Bamat5, David A Munson6, Lihai Song2, Yoav Dori3, Matthew J Gillespie3, Jonathan J Rome3, Andrew C Glatz7.   

Abstract

BACKGROUND: The risks and benefits of pharmacologic treatment and operative closure of patent ductus arteriosus (O-PDA) in premature infants remain controversial. Recent series have demonstrated the feasibility of transcatheter PDA closure (TC-PDA) in increasingly small infants. The effect of this change on practice has not been evaluated.
METHODS: A multicenter observational study of infants treated in neonatal intensive care units in hospitals contributing data to the Pediatric Health Information Systems Database from January 2007 to December 2017 was performed to study trends in the propensities for (1) mechanical closure of PDA and (2) TC-PDA versus O-PDA, as well as interhospital variation in practice.
RESULTS: A total of 6,214 subjects at 44 hospitals were studied (5% TC-PDA). Subject median gestational age was 25 weeks (interquartile range: 24-27 weeks). Median age at closure was 24 days (interquartile range: 14-36 days). The proportion of all neonatal intensive care unit patients undergoing either O-PDA or TC-PDA decreased (3.1% in 2007 and 0.7% in 2017, P < .001), whereas the proportion in which TC-PDA was used increased significantly (0.1% in 2007 to 29.0% in 2017). Case-mix-adjusted multivariable models similarly demonstrated increasing propensity to pursue TC-PDA (odds ratio [OR] 1.66 per year, P < .001) with acceleration of the trend after 2014 (OR 2.46 per year, P < .001) as well as significant practice variation (P < .001, median OR 4.6) across the study period.
CONCLUSIONS: In the face of decreasing closure of PDA, the use of TC-PDA increased dramatically with significant practice variability. This demonstrates that there is equipoise for potential clinical trials.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31654942      PMCID: PMC6861695          DOI: 10.1016/j.ahj.2019.08.009

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  36 in total

1.  Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression.

Authors:  Klaus Larsen; Juan Merlo
Journal:  Am J Epidemiol       Date:  2005-01-01       Impact factor: 4.897

2.  Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry.

Authors:  Ravi S Hira; Kevin Kennedy; Hani Jneid; Mahboob Alam; Sukhdeep S Basra; Laura A Petersen; Christie M Ballantyne; Vijay Nambi; Paul S Chan; Salim S Virani
Journal:  J Am Coll Cardiol       Date:  2014-05-07       Impact factor: 24.094

3.  Variation in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the IMproving Pediatric and Adult Congenital Treatment (IMPACT) registry.

Authors:  Michael L O'Byrne; Kevin F Kennedy; Jonathan J Rome; Andrew C Glatz
Journal:  Am Heart J       Date:  2017-11-02       Impact factor: 4.749

4.  Trends in pulmonary valve replacement in children and adults with tetralogy of fallot.

Authors:  Michael L O'Byrne; Andrew C Glatz; Laura Mercer-Rosa; Matthew J Gillespie; Yoav Dori; Elizabeth Goldmuntz; Steven Kawut; Jonathan J Rome
Journal:  Am J Cardiol       Date:  2014-10-16       Impact factor: 2.778

5.  Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).

Authors:  Barbara Schmidt; Robin S Roberts; Avroy Fanaroff; Peter Davis; Haresh M Kirpalani; Chuks Nwaesei; Michael Vincer
Journal:  J Pediatr       Date:  2006-06       Impact factor: 4.406

6.  Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services.

Authors:  C Feudtner; R M Hays; G Haynes; J R Geyer; J M Neff; T D Koepsell
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

7.  Surgical Ligation Versus Percutaneous Closure of Patent Ductus Arteriosus in Very Low-Weight Preterm Infants: Which are the Real Benefits of the Percutaneous Approach?

Authors:  A Rodríguez Ogando; I Planelles Asensio; A Rodríguez Sánchez de la Blanca; F Ballesteros Tejerizo; M Sánchez Luna; J M Gil Jaurena; C Medrano López; J L Zunzunegui Martínez
Journal:  Pediatr Cardiol       Date:  2017-11-08       Impact factor: 1.655

Review 8.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

9.  Percutaneous closure of patent ductus arteriosus in small infants with significant lung disease may offer faster recovery of respiratory function when compared to surgical ligation.

Authors:  Anas A Abu Hazeem; Matthew J Gillespie; Haley Thun; David Munson; Matthew C Schwartz; Yoav Dori; Jonathan J Rome; Andrew C Glatz
Journal:  Catheter Cardiovasc Interv       Date:  2013-07-01       Impact factor: 2.692

10.  Patent Ductus Arteriosus in Preterm Infants.

Authors:  William E Benitz
Journal:  Pediatrics       Date:  2015-12-15       Impact factor: 7.124

View more
  7 in total

1.  Hospital variation in neonatal echocardiography among very preterm infants at US children's hospitals.

Authors:  Brian C King; Joseph Hagan; Troy Richardson; Jay Berry; Jonathan L Slaughter
Journal:  J Perinatol       Date:  2022-09-26       Impact factor: 3.225

2.  Transcatheter Occlusion of a Patent Ductus Arteriosus for a Symptomatic Left-to-Right Shunt.

Authors:  Papus Keita; Frank Han; Nicholas J Peterman; Sandor Toledo; Anthony Munaco
Journal:  Cureus       Date:  2022-05-04

3.  Trends in Discharge Prescription of Digoxin After Norwood Operation: An Analysis of Data from the Pediatric Health Information System (PHIS) Database.

Authors:  Michael L O'Byrne; Lihai Song; Jing Huang; David J Goldberg; Monique M Gardner; Chitra Ravishankar; Jonathan J Rome; Andrew C Glatz
Journal:  Pediatr Cardiol       Date:  2021-02-02       Impact factor: 1.655

4.  Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases.

Authors:  Michael L O'Byrne; Jennifer A Faerber; Hannah Katcoff; Jing Huang; Jonathan B Edelson; David M Finkelstein; Bethan A Lemley; Christopher M Janson; Catherine M Avitabile; Andrew C Glatz; David J Goldberg
Journal:  Am Heart J       Date:  2021-09-25       Impact factor: 4.749

5.  Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus.

Authors:  Qintao Cui; Xiaochen Liu; Guobao Su; Chaoyuan Zhou; Junhua Wang
Journal:  Transl Pediatr       Date:  2021-10

6.  Variation in the use of pulmonary vasodilators in children and adolescents with pulmonary hypertension: a study using data from the MarketScan® insurance claims database.

Authors:  Michael L O'Byrne; Jennifer A Faerber; Hannah Katcoff; David B Frank; Alex Davidson; Therese M Giglia; Catherine M Avitabile
Journal:  Pulm Circ       Date:  2020-10-27       Impact factor: 3.017

7.  Trend and Outcomes for Surgical Versus Transcatheter Patent Ductus Arteriosus Closure in Neonates and Infants at US Children's Hospitals.

Authors:  Michael T Kuntz; Steven J Staffa; Dionne Graham; David Faraoni; Philip Levy; James DiNardo; Nicola Maschietto; Viviane G Nasr
Journal:  J Am Heart Assoc       Date:  2021-12-31       Impact factor: 6.106

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.